 |
| 15-Jul-09 | Reiterated |
RBC Capital Mkts |
Sector Perform |
$54 → $60 |
|
| 15-Jul-09 | Reiterated |
Credit Suisse |
Neutral |
$57 → $61 |
|
| 05-Jun-09 | Reiterated |
Credit Suisse |
Neutral |
$55 → $57 |
|
| 29-May-09 | Initiated |
Piper Jaffray |
Neutral |
|
|
| 29-Apr-09 | Initiated |
Standpoint Research |
Buy |
|
|
| 20-Apr-09 | Upgrade |
Wachovia |
Mkt Perform → Outperform |
|
|
| 15-Apr-09 | Reiterated |
Credit Suisse |
Neutral |
$58 → $55 |
|
| 20-Mar-09 | Upgrade |
UBS |
Neutral → Buy |
|
|
| 26-Feb-09 | Initiated |
RBC Capital Mkts |
Sector Perform |
|
|
| 21-Jan-09 | Reiterated |
Stanford Research |
Buy |
$70 → $66 |
|
| 21-Jan-09 | Reiterated |
Credit Suisse |
Neutral |
$66 → $64 |
|
| 01-Dec-08 | Reiterated |
Leerink Swann |
Mkt Perform |
$71 → $62.50 |
|
| 29-Oct-08 | Downgrade |
JP Morgan |
Overweight → Neutral |
|
|
| 15-Aug-08 | Downgrade |
UBS |
Buy → Neutral |
|
|
| 16-Jul-08 | Reiterated |
Deutsche Securities |
Buy |
$70 → $71 |
|
| 02-Jul-08 | Reiterated |
UBS |
Buy |
$75 → $73 |
|
| 23-Jun-08 | Initiated |
Leerink Swann |
Mkt Perform |
|
|
| 16-Apr-08 | Reiterated |
Deutsche Securities |
Buy |
$74 → $70 |
|
| 23-Jan-08 | Upgrade |
Stanford Research |
Hold → Buy |
|
|
| 16-Jan-08 | Reiterated |
Deutsche Securities |
Buy |
$71 → $74 |
|
|
|
| 09-Feb-10 03:49PM | Becton Recalls Catheters Zacks.com |
| 01:38PM | Slowing Down in Emerging Markets at Motley Fool |
| 01:34PM | Toyota's Problems: 8.5 Million and Counting at Motley Fool |
| 01:25PM | Which Stocks Will Be 2020's 10-Baggers? at Motley Fool |
| 01:24PM | How Rich Investors Stay Rich at Motley Fool |
| 12:50PM | Your Ticket to Country Club Riches at Motley Fool |
| 12:30PM | [$$] Some Gray Amid the Black-and-White Thinking at RealMoney by TheStreet.com |
| 10:52AM | Why I Love Dividends at Seeking Alpha |
| 10:39AM | China Prefers Apple to Google: Today's Outrage at TheStreet.com |
| 10:39AM | China Snubs Google Again: Today's Outrage at TheStreet.com |
| 10:15AM | 3 Reasons to Move Beyond Index Funds at Motley Fool |
| 09:44AM | 5-Star Stocks Poised to Pop: ISTA Pharmaceuticals at Motley Fool |
| 09:14AM | Traders Buy 'Quality,' Reject Rapid-Fire Roots at CNBC |
| 08:01AM | UPDATE - Crucell seeking new growth engine, to boost R&D at Reuters |
| 05:16AM | [$$] CIC: Not Such a Scary Wolf at The Wall Street Journal Online |
| 08-Feb-10 04:29PM | Getting Defensive with Consumer ETFs at Seeking Alpha |
| 03:07PM | Alkermes Retains Neutral Rec Zacks.com |
| 01:41PM | Trusting in Dividends at Barrons.com |
| 01:27PM | Halftime Report: How Deep Will Correction Get? at CNBC |
| 12:43PM | Vitaliy Katsenelson Reveals "The Perfect Stock for This Economy" TechTicker |
| 11:58AM | [audio] Closing Bell from MarketWatch Radio Network [1.0 min] at MarketWatch |
| 11:55AM | Correction is Healthy - and a Buying Opportunity: Strategist at CNBC |
| 11:48AM | Make Millions From Thousands at Motley Fool |
| 11:38AM | Better Investment: Visa or MasterCard? at Motley Fool |
| 11:33AM | 4-Star Stocks Poised to Pop: RTI Biologics at Motley Fool |
| 10:50AM | 5-Star Stocks Poised to Pop: Darling International at Motley Fool |
| 10:28AM | Traders Send Select Stem Cell Shares Soaring Indie Research |
| 09:00AM | SMC Accepts Janssen-Cilag's Stelara(R) Black Triangle Drug for use in NHS Scotland for the Treatment of Moderate to Severe Plaque Psoriasis PR Newswire |
| 07-Feb-10 09:21AM | This Week's 'Barron's' Roundup at TheStreet.com |
| 05-Feb-10 07:51PM | Judge allows lawsuits vs Wal-Mart, J&J over shampoo at Reuters |
| 04:50PM | S&P rates Berkshire Hathaway's $8B in notes 'AA+' AP |
| 04:44PM | JOHNSON & JOHNSON Files SEC form 8-K, Other Events EDGAR Online |
| 03:00PM | Toyota's long climb comes to an abrupt halt at FT.com |
| 01:22PM | The Profit Principle at Forbes.com |
| 12:07PM | Stalled Health Care Bill Leaves Drug Makers in Regulatory Limbo at The New York Times |
| 12:00PM | Marketing In A Weak Economy at Forbes.com |
| 11:04AM | Now Is the Time to Upgrade Your Stocks at Motley Fool |
| 10:45AM | Toyota CEO breaks silence amid recall crisis AP |
| 09:27AM | Baxter Downgraded Zacks.com |
| 09:12AM | Ahead of the Bell: Alkermes upgraded on 3Q results AP |
| 07:30AM | Toyota: How to Kill One of the World's Most Powerful Brands at Seeking Alpha |
| 07:00AM | You Missed the Bottom. Now What? at Motley Fool |
| 05:00AM | Dow Stocks -- The Top Six Picks at TheStreet.com |
| 01:30AM | 3 Stocks Going Ex-Dividend Third Week of February at Seeking Alpha |
| 04-Feb-10 11:53PM | Expect Further 5% Correction, At Least: Strategist at CNBC |
| 07:43PM | Test of "artificial pancreas" offers diabetes hope at Reuters |
| 07:21PM | 'Fast Money' Recap: What to Do at TheStreet.com |
| 06:21PM | Alkermes reports 3Q loss, smaller than expected AP |
| 05:04PM | S&P cuts Berkshire's rating, cites Burlington deal AP |
| 04:13PM | [audio] Mark Hulbert tackles the Super Bowl Predictor [3.5 min] at MarketWatch |
| 03:18PM | Coroner: Casey Johnson's death diabetes related AP |
| 02:52PM | Buy These 4 High-Quality Large Caps: Chief Investor at CNBC |
| 02:47PM | Like Its Cars, Toyota's Woes Aren't Stopping at Motley Fool |
| 12:52PM | Buffett Wishes He Could Buy These Stocks at Motley Fool |
| 12:40PM | Berkshire Hathaway Loses S&P AAA Rating at Fox Business |
| 10:16AM | 4-Star Stocks Poised to Pop: Myriad Genetics at Motley Fool |
| 10:09AM | Healthy baby campaign uses texts to reach mothers AP |
| 10:01AM | Allergan Beats, Outlook Disappoints Zacks.com |
| 09:33AM | Dividend Investors Get Paid for Waiting at Seeking Alpha |
| 08:31AM | Alkermes Testing its Version of Popular Schizophrenia Drug at TheStreet.com |
| 08:31AM | Alkermes Testing Schizophrenia Drug at TheStreet.com |
| 07:00AM | You May Have This One Wrong -- Here's Why at Motley Fool |
| 12:55AM | 3 Simple Keys to Dividend Investing at Seeking Alpha |
| 03-Feb-10 11:32PM | Healthy baby campaign uses texts to reach mothers AP |
| 04:45PM | Pfizer Drags Down Pharma at Forbes.com |
| 03:31PM | Wyeth Can't Save Pfizer at Motley Fool |
| 01:58PM | This Simple Switch Could Save Your Retirement at Motley Fool |
| 12:30PM | Pfizer Miss Leads Pharma Lower at Forbes.com |
| 10:28AM | 5-Star Stocks Poised to Pop: SABESP at Motley Fool |
| 10:03AM | Pfizer Off 2% As 2010 Targets Miss; Posts Revised 2012 Targets at Barrons.com |
| 07:08AM | 6 Stellar Excuses to Stay Stubbornly Bullish at Seeking Alpha |
| 06:54AM | Acquisitions In Home Health Care And Medical Diagnostics Sector Will Rise In 2010 According To RBC Capital Markets Expert Equity Analyst: Strong Cash Flow And Personalized Medicine Are Drivers Wall Street Transcript |
| 05:00AM | [video] Go High-Quality with JNJ: China Watch at TheStreet.com |
| 02-Feb-10 03:54PM | Defense! Defense! at Motley Fool |
| 03:41PM | Dow 8,000? at Motley Fool |
| 03:25PM | How Toyota?s Pain is Detroit?s Gain at Minyanville.com |
| 02:16PM | Foolish Forecast: First Look at Pfizer Plus at Motley Fool |
| 10:35AM | 5-Star Stocks Poised to Pop: Western Union at Motley Fool |
| 09:41AM | CORRECTED - Toyota's other pedal problem: Lawsuits at Reuters |
| 09:32AM | Becton Stays Neutral Zacks.com |
| 08:50AM | FDA Approves Allergan's Juvederm XC Zacks.com |
| 12:54AM | Boston Scientific to Pay $1.7 Billion to Settle Patent Suits at The New York Times |
| 01-Feb-10 11:11PM | [$$] Boston Scientific to Pay J&J $1.73B to Settle Stent Patent Disputes at The Wall Street Journal Online |
| 10:56PM | Swiss Tax Play Lures Business at The Wall Street Journal Online |
| 10:15PM | Energy, Metals Stocks Lead Market Higher at The Wall Street Journal Online |
| 06:15PM | Boston Scientific to pay JNJ $1.73B in settlement AP |
| 05:14PM | Toyota's other pedal problem: Lawsuits at Reuters |
| 05:12PM | Dow Makes Triple-Digit Gain at TheStreet.com |
| 04:28PM | Boston Scientific: Must Pay JNJ to Settle Patent Dispute at Seeking Alpha |
| 04:11PM | Now That's Some Expensive Risk Mitigation at Motley Fool |
| 03:55PM | Are Toyota's Troubles an Opportunity? at Motley Fool |
| 03:51PM | Stocks Bulk Up as Manufacturing Improves at TheStreet.com |
| 03:08PM | Boston Sci to pay J&J $1.73 billion in settlement Reuters |
| 03:06PM | Make Dividends Your Servant at Motley Fool |
| 01:51PM | Biotech Stocks: Drug stocks gain; Warner Chilcott shares retreat at MarketWatch |
| 01:38PM | $1.7 Billion Settlement Tops J&J's 2009 Sales of Coated Stents at The Wall Street Journal Online |
| 12:17PM | Where to Invest for the Next 10-20 Years: Strategist at CNBC |
| 11:49AM | Stocks Warm to Manufacturing Surge at TheStreet.com |
| 11:47AM | [$$] Boston Scientific To Pay J&J $1.73B To Settle Stent Patent Disputes at The Wall Street Journal Online |
| 10:39AM | 5-Star Stocks Poised to Pop: PICO at Motley Fool |
|
|
| Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide. Its Consumer segment provides products used in baby care, skin care, oral care, wound care, and women's health care fields, as well as nutritional and over-the-counter pharmaceutical products under JOHNSON'S, AVEENO, CLEAN & CLEAR, NEUTROGENA, RoC, LUBRIDERM, LISTERINE, REACH, CAREFREE, STAYFREE, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID AC names. The company's Pharmaceutical segment offers products in various therapeutic areas, such as anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology, and virology. Its products include REMICADE, a biologic to treat Crohn's disease, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis, and used to treat rheumatoid arthritis; TOPAMAX, for adjunctive and monotherapy use in epilepsy, as well as for treating migraines; PROCRIT that stimulates red blood cell production; RISPERDAL oral, a medication to treat the symptoms of schizophrenia, bipolar mania, and irritability associated with autistic behavior in indicated patients; RISPERDAL CONSTA, an injectable, and INVEGATM Extended-Release tablets to treat schizophrenia; LEVAQUIN and FLOXIN, anti-infective products; CONCERTA, a product for treating attention deficit hyperactivity disorder; ACIPHEX/PARIET, a proton pump inhibitor; and DURAGESIC/Fentanyl Transdermal, a treatment for chronic pain. Johnson & Johnson's Medical Devices and Diagnostics segment offers circulatory disease management, orthopaedic joint reconstruction and spinal care and sports medicine, surgical care and women's health, minimally invasive surgical, blood glucose monitoring and insulin delivery, and diagnostic products, as well as disposable contact lenses. The company was founded in 1886 and is based in New Brunswick, New Jersey. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Foster-Cheek Kaye I | VP, Human Resources | Dec 10 | Option Exercise | 57.08 | 96,742 | 5,522,458 | 101,171 | Dec 11 02:45 PM | | Foster-Cheek Kaye I | VP, Human Resources | Dec 10 | Sale | 64.76 | 96,742 | 6,265,012 | 4,583 | Dec 11 02:45 PM | | MULLIN LEO F | Director | Dec 04 | Option Exercise | 46.33 | 2,200 | 101,926 | 15,892 | Dec 08 03:47 PM | | CULLEN JAMES | Director | Dec 03 | Option Exercise | 46.33 | 2,200 | 101,926 | 46,331 | Dec 04 04:00 PM | | CULLEN JAMES | Director | Dec 03 | Sale | 64.65 | 2,200 | 142,230 | 44,131 | Dec 04 04:00 PM | | DEYO RUSSELL C | VP, General Counsel | Nov 24 | Option Exercise | 50.08 | 98,200 | 4,917,856 | 212,033 | Nov 24 05:37 PM | | DEYO RUSSELL C | VP, General Counsel | Nov 24 | Sale | 62.91 | 98,200 | 6,177,762 | 113,833 | Nov 24 05:37 PM | | LANGBO ARNOLD G | Director | Nov 23 | Option Exercise | 46.33 | 2,200 | 101,926 | 8,770 | Nov 25 04:55 PM | | McCoy Sherilyn S | Member, Executive Committee | Nov 23 | Option Exercise | 50.08 | 9,700 | 485,776 | 53,344 | Nov 24 05:36 PM | | DEYO RUSSELL C | VP, General Counsel | Nov 23 | Option Exercise | 50.08 | 1,800 | 90,144 | 113,833 | Nov 24 05:37 PM | | McCoy Sherilyn S | Member, Executive Committee | Nov 23 | Sale | 63.00 | 9,700 | 611,100 | 43,644 | Nov 24 05:36 PM | | COSGROVE STEPHEN J | Corporate Controller | Sep 10 | Option Exercise | 50.08 | 12,700 | 636,016 | 83,678 | Sep 11 04:40 PM | | Casey Donald M Jr. | Member, Executive Committee | Sep 10 | Option Exercise | 35.74 | 13,800 | 493,212 | 36,336 | Sep 11 04:34 PM | | Casey Donald M Jr. | Member, Executive Committee | Sep 10 | Sale | 60.68 | 13,800 | 837,384 | 22,536 | Sep 11 04:34 PM | | COSGROVE STEPHEN J | Corporate Controller | Sep 10 | Sale | 60.69 | 12,700 | 770,763 | 70,978 | Sep 11 04:40 PM | | DEYO RUSSELL C | VP, General Counsel | Sep 03 | Sale | 59.54 | 180 | 10,717 | 2,394 | Sep 04 03:40 PM | | GOGGINS COLLEEN A | Member, Executive Committee | Aug 26 | Option Exercise | 50.08 | 22,200 | 1,111,776 | 120,698 | Aug 27 05:51 PM | | GOGGINS COLLEEN A | Member, Executive Committee | Aug 26 | Sale | 60.59 | 22,200 | 1,345,098 | 98,498 | Aug 27 05:51 PM | | GOGGINS COLLEEN A | Member, Executive Committee | Aug 25 | Option Exercise | 50.08 | 1,800 | 90,144 | 99,969 | Aug 27 05:51 PM | | PEREZ WILLIAM D | Director | Aug 06 | Buy | 60.00 | 1,000 | 60,000 | 11,000 | Aug 10 04:09 PM | | WELDON WILLIAM C | Chairman/CEO | Jul 15 | Option Exercise | 50.08 | 158,200 | 7,922,656 | 365,732 | Jul 16 05:14 PM | | WELDON WILLIAM C | Chairman/CEO | Jul 15 | Sale | 58.74 | 158,200 | 9,292,668 | 207,532 | Jul 16 05:14 PM | | DEYO RUSSELL C | VP, General Counsel | Jun 04 | Sale | 55.76 | 60 | 3,346 | 2,219 | Jun 08 02:10 PM | | Caruso Dominic J | Chief Financial Officer | May 06 | Option Exercise | 47.39 | 38,320 | 1,815,985 | 51,589 | May 07 05:52 PM | | Caruso Dominic J | Chief Financial Officer | May 06 | Sale | 54.97 | 38,320 | 2,106,450 | 13,269 | May 07 05:52 PM | | WELDON WILLIAM C | Chairman/CEO | Feb 23 | Option Exercise | 50.08 | 1,800 | 90,144 | 198,707 | Feb 24 05:58 PM | | PEREZ WILLIAM D | Director | Feb 19 | Buy | 55.81 | 2,000 | 111,620 | 10,000 | Feb 20 04:38 PM | | COSGROVE STEPHEN J | Corporate Controller | Feb 13 | Option Exercise | 0.00 | 1,928 | 0 | 71,740 | Feb 17 06:10 PM | | Casey Donald M Jr. | Member, Executive Committee | Feb 13 | Option Exercise | 0.00 | 7,590 | 0 | 24,815 | Feb 17 06:05 PM | | Caruso Dominic J | Chief Financial Officer | Feb 13 | Option Exercise | 0.00 | 5,142 | 0 | 14,816 | Feb 17 05:59 PM | | POON CHRISTINE A | Vice Chairman | Feb 13 | Option Exercise | 0.00 | 17,141 | 0 | 61,942 | Feb 17 07:12 PM | | WELDON WILLIAM C | Chairman/CEO | Feb 13 | Option Exercise | 0.00 | 37,710 | 0 | 210,066 | Feb 17 06:59 PM | | VALERIANI NICHOLAS J | VP, Strategy & Growth | Feb 13 | Option Exercise | 0.00 | 7,713 | 0 | 60,881 | Feb 17 06:53 PM | | GOGGINS COLLEEN A | Member, Executive Committee | Feb 13 | Option Exercise | 0.00 | 9,363 | 0 | 102,830 | Feb 17 06:39 PM | | Foster-Cheek Kaye I | VP, Human Resources | Feb 13 | Option Exercise | 0.00 | 5,999 | 0 | 6,665 | Feb 17 06:30 PM | | DEYO RUSSELL C | VP, General Counsel | Feb 13 | Option Exercise | 0.00 | 9,427 | 0 | 114,913 | Feb 17 06:27 PM | | DEYO RUSSELL C | VP, General Counsel | Feb 12 | Sale | 56.41 | 323 | 18,220 | 1,662 | Feb 17 06:27 PM | | WELDON WILLIAM C | Chairman/CEO | Feb 02 | Sale | 57.69 | 1,893 | 109,207 | 0 | Feb 04 06:34 PM |
|
|
|
|
|
|
